| scholarly article | Q13442814 |
| P2093 | author name string | Olivier Micheau | |
| Alexandre Morizot | |||
| Poul H B Sorensen | |||
| Ladislav Andera | |||
| Jean-Claude Martinou | |||
| Olivier Gaide | |||
| Michal Koc | |||
| Syam Prakash Somasekharan | |||
| P2860 | cites work | Membrane remodeling induced by the dynamin-related protein Drp1 stimulates Bax oligomerization | Q24300125 |
| Identification and characterization of a new member of the TNF family that induces apoptosis | Q24318423 | ||
| X-linked IAP is a direct inhibitor of cell-death proteases | Q24318710 | ||
| Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family | Q24320301 | ||
| The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases | Q24532851 | ||
| Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death | Q24630370 | ||
| Cell motility through plasma membrane blebbing | Q24656957 | ||
| TRAIL receptor-2 signals apoptosis through FADD and caspase-8 | Q28142998 | ||
| Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy | Q28176737 | ||
| Caspase-3-mediated cleavage of ROCK I induces MLC phosphorylation and apoptotic membrane blebbing | Q28210013 | ||
| The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex | Q28221276 | ||
| An antagonist decoy receptor and a death domain-containing receptor for TRAIL | Q28245153 | ||
| Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors | Q28245164 | ||
| Death receptors: signaling and modulation | Q28280897 | ||
| An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. | Q53426774 | ||
| TRAIL induces proliferation of human glioma cells by c-FLIPL-mediated activation of ERK1/2. | Q53501262 | ||
| TRAIL Promotes the Survival and Proliferation of Primary Human Vascular Endothelial Cells by Activating the Akt and ERK Pathways | Q59225369 | ||
| Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates pro-survival and pro-apoptotic pathways in SK-N-MC neuronal cells | Q59225404 | ||
| Blebs lead the way: how to migrate without lamellipodia | Q28287258 | ||
| Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells | Q30305481 | ||
| Role of BAX in the apoptotic response to anticancer agents | Q31523620 | ||
| Caspase-3 is transiently activated without cell death during early antigen driven expansion of CD8(+) T cells in vivo | Q33784712 | ||
| Membrane blebbing during apoptosis results from caspase-mediated activation of ROCK I. | Q33941102 | ||
| Mitochondria as the central control point of apoptosis | Q33994978 | ||
| New insights into apoptosis signaling by Apo2L/TRAIL. | Q34022690 | ||
| c-Cbl-mediated degradation of TRAIL receptors is responsible for the development of the early phase of TRAIL resistance. | Q34277650 | ||
| Caspases in cell survival, proliferation and differentiation. | Q34652977 | ||
| Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level | Q35051505 | ||
| Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy | Q35093740 | ||
| Non-apoptotic functions of caspases in cellular proliferation and differentiation | Q35557615 | ||
| Collective cell migration in morphogenesis and cancer | Q35878896 | ||
| Mechanisms of cancer cell invasion | Q36015535 | ||
| Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. | Q36080043 | ||
| Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy | Q36112074 | ||
| BH3-only proteins in cell death initiation, malignant disease and anticancer therapy. | Q36463059 | ||
| Rho kinase in the regulation of cell death and survival | Q36755421 | ||
| TRAIL signalling: decisions between life and death. | Q36778214 | ||
| The TRAIL apoptotic pathway in cancer onset, progression and therapy | Q37278043 | ||
| Proteasome inhibitors sensitize glioma cells and glioma stem cells to TRAIL-induced apoptosis by PKCε-dependent downregulation of AKT and XIAP expressions | Q39569903 | ||
| Proteasome inhibitor sensitizes oral squamous cell carcinoma cells to TRAIL-mediated apoptosis | Q39612127 | ||
| Caspase-3 cleaves XIAP in a positive feedback loop to sensitize melanoma cells to TRAIL-induced apoptosis | Q39653516 | ||
| TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. | Q39753656 | ||
| Caspase-3 enhances lung metastasis and cell migration in a protease-independent mechanism through the ERK pathway | Q39961942 | ||
| Cross talk between apoptosis and invasion signaling in cancer cells through caspase-3 activation | Q40361024 | ||
| Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells | Q40372744 | ||
| Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells | Q40414448 | ||
| Proteinase-3 induces procaspase-3 activation in the absence of apoptosis: potential role of this compartmentalized activation of membrane-associated procaspase-3 in neutrophils | Q40425494 | ||
| Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cells | Q40604705 | ||
| Actin-binding protein requirement for cortical stability and efficient locomotion | Q41643536 | ||
| Spatio-temporal activation of caspase revealed by indicator that is insensitive to environmental effects | Q42916419 | ||
| Mutant PIK3CA licenses TRAIL and CD95L to induce non-apoptotic caspase-8-mediated ROCK activation | Q43105405 | ||
| Differential involvement of Bax and Bak in TRAIL-mediated apoptosis of leukemic T cells | Q43902939 | ||
| Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. | Q43903493 | ||
| Platelet formation is the consequence of caspase activation within megakaryocytes | Q44083637 | ||
| TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB. | Q44482351 | ||
| The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells | Q44539646 | ||
| Marginal blebbing during the early stages of TNF-induced apoptosis indicates alteration in actomyosin contractility | Q44955909 | ||
| Caspase signalling controls microglia activation and neurotoxicity. | Q53422658 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 324-336 | |
| P577 | publication date | 2013-03-01 | |
| P1433 | published in | Apoptosis | Q15749546 |
| P1476 | title | TRAIL promotes membrane blebbing, detachment and migration of cells displaying a dysfunctional intrinsic pathway of apoptosis | |
| P478 | volume | 18 |
| Q38882537 | A fate worse than death: apoptosis as an oncogenic process |
| Q41083072 | An Aqueous Extract of Marine Microalgae Exhibits Antimetastatic Activity through Preferential Killing of Suspended Cancer Cells and Anticolony Forming Activity. |
| Q90241548 | Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy |
| Q37098808 | Cardiolipin or MTCH2 can serve as tBID receptors during apoptosis |
| Q36352596 | Chemotherapy with ceramide in TNBC. |
| Q55042637 | Combined application of Embelin and tumor necrosis factor-related apoptosis-inducing ligand inhibits proliferation and invasion in osteosarcoma cells via caspase-induced apoptosis. |
| Q53701901 | Developing TRAIL/TRAIL death receptor-based cancer therapies. |
| Q37706093 | TRAIL receptor gene editing unveils TRAIL-R1 as a master player of apoptosis induced by TRAIL and ER stress |
| Q30635379 | YB-1 regulates stress granule formation and tumor progression by translationally activating G3BP1. |
Search more.